Aspira Women's Health to Present at J.P. Morgan Healthcare Conference
Ticker: AWHL · Form: 8-K · Filed: Jan 5, 2024 · CIK: 926617
| Field | Detail |
|---|---|
| Company | Aspira Women'S Health INC. (AWHL) |
| Form Type | 8-K |
| Filed Date | Jan 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: conference, presentation, corporate-event
TL;DR
**AWH presenting at JPM conference Jan 9th, watch for potential stock movement.**
AI Summary
Aspira Women's Health Inc. filed an 8-K on January 4, 2024, to disclose that they will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 10:30 AM PT. This matters to investors because it's an opportunity for the company to share updates on its business, potentially influencing stock performance based on the information presented and investor reception.
Why It Matters
This presentation could provide crucial updates on Aspira Women's Health's strategic direction, product pipeline, or financial outlook, directly impacting investor sentiment and the stock's short-term trajectory.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a conference presentation, which carries minimal direct risk to the company or its investors.
Analyst Insight
A smart investor would monitor the content of Aspira Women's Health's presentation at the J.P. Morgan Healthcare Conference on January 9, 2024, for any significant announcements that could impact future stock performance, rather than reacting solely to the announcement of the presentation itself.
Key Players & Entities
- Aspira Women's Health Inc. (company) — the registrant filing the 8-K
- J.P. Morgan Healthcare Conference (event) — where Aspira Women's Health will present
- January 4, 2024 (date) — date of earliest event reported in the 8-K
- January 9, 2024 (date) — date of the presentation
- 10:30 AM PT (time) — scheduled time of the presentation
Forward-Looking Statements
- Aspira Women's Health Inc. stock (AWH) may experience increased trading volume around January 9, 2024. (AWH) — medium confidence, target: 2024-01-09
- The company's presentation at the J.P. Morgan Healthcare Conference will likely include updates on their diagnostic products or strategic initiatives. (Aspira Women's Health Inc.) — high confidence, target: 2024-01-09
FAQ
What is the purpose of Aspira Women's Health Inc.'s 8-K filing dated January 4, 2024?
The 8-K filing is to announce that Aspira Women's Health Inc. will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference.
When and where will Aspira Women's Health Inc. present at the J.P. Morgan Healthcare Conference?
Aspira Women's Health Inc. will present on January 9, 2024, at 10:30 AM PT, at the 42nd Annual J.P. Morgan Healthcare Conference.
What is the trading symbol for Aspira Women's Health Inc. and on which exchange is it registered?
The trading symbol for Aspira Women's Health Inc. is AWH, and its Common Stock is registered on the Nasdaq Capital Market.
What is the business address of Aspira Women's Health Inc. as stated in the filing?
The business address of Aspira Women's Health Inc. is 12117 Bee Caves Road, Building III, Suite 100, Austin, Texas 78738.
Under which item information categories was this 8-K filed?
This 8-K was filed under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-01-05 16:39:44
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Market
Filing Documents
- awh-20240104x8k.htm (8-K) — 71KB
- awh-20240104xex99_1.htm (EX-99.1) — 26KB
- awh-20240104xex99_1g001.jpg (GRAPHIC) — 104KB
- awh-20240104xex99_1g002.jpg (GRAPHIC) — 66KB
- awh-20240104xex99_1g003.jpg (GRAPHIC) — 107KB
- awh-20240104xex99_1g004.jpg (GRAPHIC) — 155KB
- awh-20240104xex99_1g005.jpg (GRAPHIC) — 170KB
- awh-20240104xex99_1g006.jpg (GRAPHIC) — 51KB
- awh-20240104xex99_1g007.jpg (GRAPHIC) — 66KB
- awh-20240104xex99_1g008.jpg (GRAPHIC) — 76KB
- awh-20240104xex99_1g009.jpg (GRAPHIC) — 127KB
- awh-20240104xex99_1g010.jpg (GRAPHIC) — 45KB
- awh-20240104xex99_1g011.jpg (GRAPHIC) — 116KB
- awh-20240104xex99_1g012.jpg (GRAPHIC) — 127KB
- awh-20240104xex99_1g013.jpg (GRAPHIC) — 137KB
- awh-20240104xex99_1g014.jpg (GRAPHIC) — 142KB
- awh-20240104xex99_1g015.jpg (GRAPHIC) — 33KB
- awh-20240104xex99_1g016.jpg (GRAPHIC) — 180KB
- awh-20240104xex99_1g017.jpg (GRAPHIC) — 148KB
- awh-20240104xex99_1g018.jpg (GRAPHIC) — 122KB
- awh-20240104xex99_1g019.jpg (GRAPHIC) — 126KB
- awh-20240104xex99_1g020.jpg (GRAPHIC) — 106KB
- awh-20240104xex99_1g021.jpg (GRAPHIC) — 33KB
- awh-20240104xex99_1g022.jpg (GRAPHIC) — 128KB
- awh-20240104xex99_1g023.jpg (GRAPHIC) — 109KB
- awh-20240104xex99_1g024.jpg (GRAPHIC) — 127KB
- awh-20240104xex99_1g025.jpg (GRAPHIC) — 133KB
- awh-20240104xex99_1g026.jpg (GRAPHIC) — 162KB
- awh-20240104xex99_1g027.jpg (GRAPHIC) — 119KB
- awh-20240104xex99_1g028.jpg (GRAPHIC) — 113KB
- awh-20240104xex99_1g029.jpg (GRAPHIC) — 130KB
- awh-20240104xex99_1g030.jpg (GRAPHIC) — 36KB
- awh-20240104xex99_1g031.jpg (GRAPHIC) — 109KB
- awh-20240104xex99_1g032.jpg (GRAPHIC) — 97KB
- awh-20240104xex99_1g033.jpg (GRAPHIC) — 43KB
- 0000926617-24-000002.txt ( ) — 5104KB
- awh-20240104.xsd (EX-101.SCH) — 2KB
- awh-20240104_lab.xml (EX-101.LAB) — 15KB
- awh-20240104_pre.xml (EX-101.PRE) — 11KB
- awh-20240104x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 4, 2024, Aspira Women's Health Inc. (the "Company") presented an overview of the Company's product pipeline status. A copy of the Slide Deck is furnished as Exhibit 99.1 to this Current Report on Form 8-K filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Slide Deck Presented by Aspira Women's Health Inc. On January 4, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: January 5, 2024 By: /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer